12:01 PM EDT, 08/06/2026 (MT Newswires) -- Genmab (GMAB.CO) raised its earnings guidance for 2026, thanks to higher total royalty revenue from multiple myeloma drug Darzalex and net sales of diffuse large B-cell lymphoma treatment Epkinly. The Danish biotechnology company now expects revenue of between $4.33 billion and $4.53 billion, up from its previous forecast of between $4.07 billion and $4.4 billion, according to a Thursday release. Genmab also anticipates gross profit in the range of $4.02 billion to $4.2 billion, up from $3.81 billion to $4.11 billion. Adjusted operating profit is expected to be between $1.07 billion and $1.39 billion, compared with the prior range of $900 million to $1.4 billion.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.